These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 11503311

  • 1. ['Variant of Creutzfeldt-Jacob disease and blood transfusion'; report of the Dutch Health Council].
    van Aken WG.
    Ned Tijdschr Geneeskd; 2001 Jul 28; 145(30):1444-7. PubMed ID: 11503311
    [Abstract] [Full Text] [Related]

  • 2. Impact of vCJD on blood supply.
    Seitz R, von Auer F, Blümel J, Burger R, Buschmann A, Dietz K, Heiden M, Hitzler WE, Klamm H, Kreil T, Kretzschmar H, Nübling M, Offergeld R, Pauli G, Schottstedt V, Volkers P, Zerr I.
    Biologicals; 2007 Apr 28; 35(2):79-97. PubMed ID: 17320412
    [Abstract] [Full Text] [Related]

  • 3. [The risk of variant Creutzfeldt-Jakob disease in the Netherlands and the effect of preventive measures].
    Kersseboom R, Koekoek SC, Richardus JH.
    Ned Tijdschr Geneeskd; 2002 Apr 20; 146(16):754-9. PubMed ID: 11998352
    [Abstract] [Full Text] [Related]

  • 4. Variant Creutzfeldt-Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty.
    Farrugia A, Ironside JW, Giangrande P.
    Vox Sang; 2005 Nov 20; 89(4):186-92. PubMed ID: 16262750
    [Abstract] [Full Text] [Related]

  • 5. Variant Creutzfeldt-Jakob disease in a transfusion recipient: coincidence or cause?
    Chohan G, Llewelyn C, Mackenzie J, Cousens S, Kennedy A, Will R, Hewitt P.
    Transfusion; 2010 May 20; 50(5):1003-6. PubMed ID: 20230536
    [Abstract] [Full Text] [Related]

  • 6. Balancing evidence and public opinion in health technology assessments: the case of leukoreduction.
    Cleemput I, Leys M, Ramaekers D, Bonneux L.
    Int J Technol Assess Health Care; 2006 May 20; 22(4):403-7. PubMed ID: 16984672
    [Abstract] [Full Text] [Related]

  • 7. The application of the precautionary principle to the blood system: the Canadian blood system's vCJD donor deferral policy.
    Wilson K, Wilson M, Hébert PC, Graham I.
    Transfus Med Rev; 2003 Apr 20; 17(2):89-94. PubMed ID: 12733102
    [Abstract] [Full Text] [Related]

  • 8. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products.
    Ludlam CA, Turner ML.
    Br J Haematol; 2006 Jan 20; 132(1):13-24. PubMed ID: 16371015
    [Abstract] [Full Text] [Related]

  • 9. Bovine spongiform encephalopathy in Israel: implications for human health.
    Nitzan-Kaluski D, Leventhal A.
    Isr Med Assoc J; 2003 Sep 20; 5(9):662-5. PubMed ID: 14509159
    [Abstract] [Full Text] [Related]

  • 10. Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: precautionary measures and efficacy of manufacturing processes in prion removal.
    Flan B, Arrabal S.
    Transfus Clin Biol; 2007 May 20; 14(1):51-62. PubMed ID: 17540602
    [Abstract] [Full Text] [Related]

  • 11. Current strategies to prevent transmission of prions by human plasma derivatives.
    Burnouf T, Padilla A.
    Transfus Clin Biol; 2006 Nov 20; 13(5):320-8. PubMed ID: 17254822
    [Abstract] [Full Text] [Related]

  • 12. [vCJD epidemiology in France].
    Brandel JP, Salomon D, Alpérovitch A.
    Transfus Clin Biol; 2006 Nov 20; 13(5):304-6. PubMed ID: 17188544
    [Abstract] [Full Text] [Related]

  • 13. The risk of accidental transmission of transmissible spongiform encephalopathy: identification of emerging issues.
    Ramasamy I.
    Public Health; 2004 Sep 20; 118(6):409-20. PubMed ID: 15313594
    [Abstract] [Full Text] [Related]

  • 14. Geographic exposure risk of variant Creutzfeldt-Jakob disease in US blood donors: a risk-ranking model to evaluate alternative donor-deferral policies.
    Yang H, Huang Y, Gregori L, Asher DM, Bui T, Forshee RA, Anderson SA.
    Transfusion; 2017 Apr 20; 57(4):924-932. PubMed ID: 28261810
    [Abstract] [Full Text] [Related]

  • 15. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products.
    Turner ML, Ludlam CA.
    Br J Haematol; 2009 Jan 20; 144(1):14-23. PubMed ID: 18950452
    [Abstract] [Full Text] [Related]

  • 16. Variant Creutzfeldt-Jakob disease and the acquired and transmissible spongiform encephalopathies.
    Beisel CE, Morens DM.
    Clin Infect Dis; 2004 Mar 01; 38(5):697-704. PubMed ID: 14986255
    [Abstract] [Full Text] [Related]

  • 17. Mammalian brain consumption by blood donors in the United States: brains today, deferred tomorrow?
    Schreiber GB, Sanchez AM, Garratty G, Nass CC, Tu Y, Busch MP, Retrovirus Epidemiology Donor Study.
    Transfusion; 2004 May 01; 44(5):667-74. PubMed ID: 15104646
    [Abstract] [Full Text] [Related]

  • 18. Transfusion transmission of human prion diseases.
    Zou S, Fang CT, Schonberger LB.
    Transfus Med Rev; 2008 Jan 01; 22(1):58-69. PubMed ID: 18063192
    [Abstract] [Full Text] [Related]

  • 19. Strategies to reduce transfusion acquired vCJD.
    Wallis JP.
    Transfus Med; 2011 Feb 01; 21(1):1-6. PubMed ID: 21070399
    [Abstract] [Full Text] [Related]

  • 20. Risk of variant Creuzfeldt-Jakob disease from factor concentrates: current perspectives.
    Farrugia A.
    Haemophilia; 2002 May 01; 8(3):230-5. PubMed ID: 12010416
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.